While tumour prognosis and survival in negative anti-Yo antibody PCD patients is similar to those with normal breast cancer, anti-Yo antibody positive patients are reported to have a more aggressive cerebellar disease course with more than 90 % eventually requiring an assistive device for ambulation and significantly poorer overall survival (median 100 months) [11, 14]. This evidence concerns the gene CDR2 and breast carcinoma.